Vittoria Biotherapeutics Announces Peer-Reviewed Publication in Science Immunology
2024年7月22日 - 9:00PM
Vittoria Biotherapeutics, a clinical-stage cell therapy company,
announces a recent publication by investigators at the University
of Pennsylvania in the peer-reviewed journal, Science Immunology.
The publication details the critical influence of CD5, a key
immunomodulatory protein, on engineered T-cell therapies, which is
the foundational basis of the company’s proprietary Senza5TM
platform. This technology, developed by the University of
Pennsylvania and exclusively licensed to Vittoria, leverages the
therapeutic potential of CD5 modulation to enhance the efficacy of
CAR T-cell therapies and underscores its utility across multiple
hematological and solid tumor animal models.
“We are incredibly excited about the findings
shared in Science Immunology, which support the clinical
translation of our Senza5TM platform and exemplify Vittoria’s
commitment to pioneering potent and innovative solutions to advance
the field of enabled, autologous cell therapies,” said Nicholas
Siciliano, Ph.D., Chief Executive Officer of Vittoria
Biotherapeutics. “Despite significant advances in cell therapy
across various diseases, considerable unmet needs remain for
certain cancers and chronic diseases. This publication comes at a
pivotal time as we initiate the clinical trial for our lead
program, VIPER-101 for the treatment of T-cell lymphoma.”
The research was conducted in the laboratory of
Marco Ruella, M.D., a Physician-Scientist in the Perelman School of
Medicine at the University of Pennsylvania, who is also the
scientific founder of Vittoria Biotherapeutics. Dr. Ruella, the
senior author of the study, added, “I am honored to see our seminal
study on the role of CD5 in engineered cell therapies published in
Science Immunology. The study highlights the ongoing innovation and
continued commitment to advance the field of cell therapy and
cancer research at the University of Pennsylvania. Recognizing the
transformative potential of this technology, we founded Vittoria to
accelerate its translation into the clinic. The first clinical
candidate developed from this research is now being evaluated in a
first-in-human clinical trial at Penn Medicine as a potential new
treatment for T-cell lymphoma, a disease with significant unmet
therapeutic need.”
The preclinical study, titled “CD5 Deletion
Enhances the Anti-Tumor Activity of Adoptive T Cell
Therapies,” describes the benefits of the approach of modulating
the CD5 signaling pathway and utilizing a proprietary five-day
manufacturing process to enhance CAR T potency, durability, and
accessibility. These features may address existing challenges with
current CAR T-cell treatments including CAR T exhaustion,
suboptimal efficacy, and manufacturing inefficiencies. To learn
more in-depth about these approaches, which underline Vittoria’s
Senza5TM platform, the full publication is available here:
https://www.science.org/doi/10.1126/sciimmunol.adn6509.
Ruchi Patel, Ph.D., the lead author of the study
and former graduate student in the Ruella laboratory at the
University of Pennsylvania who recently joined Vittoria’s
scientific team, added, “I am thrilled to see our work published in
such a prestigious journal, and excited to contribute to the
clinical translation of this groundbreaking technology in my new
role at Vittoria. This brings us one step closer to enabling the
next generation of transformative cell therapies and potentially
improving patient outcomes.”
Vittoria's VIPER-101 clinical trial is now open
for enrollment for the treatment of T-cell lymphoma. Information
about the trial can be found at:
https://clinicaltrials.gov/study/NCT06420089?a=1. Initial clinical
data is expected in early 2025 and will provide valuable insights
into the Senza5 platform technology, paving the way for more
effective cell therapies that can transform the treatment landscape
for patients with cancer and autoimmune diseases.
Editor’s Note: Ruella is the scientific founder
of, a paid consultant for, and an equity holder in, Vittoria
Biotherapeutics. The University of Pennsylvania holds equity in
Vittoria Biotherapeutics, has received sponsored research funding
from Vittoria, has licensed certain intellectual property to
Vittoria and may receive future research funding and financial
consideration based on development and commercialization of certain
products by Vittoria.
About
Senza5TM
Senza5TM is a proprietary cell therapy
engineering and manufacturing platform that combines the power of
genetic engineering and a proprietary five-day manufacturing
process to maximize stemness, durability, and efficacy of its
produced cell therapies by disabling the CD5 signaling pathway on
engineered CAR T cells and bypassing CD5's immunosuppressive
effects to amplify the therapy’s antitumor activity. The expedited
five-day manufacturing process further enhances stemness, which
promotes greater in vivo expansion and durability and the potential
for longer-lasting responses. Senza5 can be widely utilized to
improve the efficacy of engineered T-cell therapies by acting on
the fundamental biology of T cells.
About Vittoria
Biotherapeutics
Vittoria Biotherapeutics, Inc., a clinical-stage
cell therapy company, is developing novel CAR T-cell therapies that
transcend the limitations of current cell therapies. Based on
technology exclusively licensed from the University of
Pennsylvania, the Company’s proprietary Senza5TM platform unlocks
the cytotoxic potential of engineered T cells and utilizes a
five-day manufacturing process to maximize stemness, durability,
and potency. By acting on the fundamental biology of T cells,
Senza5 can be used to improve the efficacy of engineered T-cell
therapies with pipeline applications in oncology and autoimmune
diseases. To learn more, visit vittoriabio.com and follow us
on LinkedIn.
Investor Contact
Vittoria Biotherapeutics, Inc. Nicholas A. Siciliano, Ph.D.
Chief Executive Officer +1 215-600-1380
Media Contact
LifeSci Communications Michael Tattory Associate Director
LifeSci Communications +1 609-802-6265